A former failure in PhII, the go-go FDA says it’s ready to consider an accelerated shortcut for Ultragenyx's UX007
More than a year after Ultragenyx $RARE announced the failure of a Phase II study for its seizure medication UX007, the rare disease specialist says …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
